Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Actuate Therapeutics Inc.
NRG Oncology
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Eli Lilly and Company
Gilead Sciences
Pfizer
AstraZeneca
Hoffmann-La Roche
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
NanOlogy, LLC
Regeneron Pharmaceuticals
Inhibrx Biosciences, Inc
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
Fundación GECP
University of Kentucky
Weill Medical College of Cornell University
Phanes Therapeutics
BeiGene
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Prestige Biopharma Limited
NanOlogy, LLC
Bristol-Myers Squibb
Fundación GECP
Fox Chase Cancer Center
EpicentRx, Inc.
Latin American Cooperative Oncology Group
Samsung Bioepis Co., Ltd.
BeiGene
Galvanize Therapeutics, Inc.
Rutgers, The State University of New Jersey
Humanetics Corporation
Sumitomo Pharma America, Inc.